相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Potential of Inaccurate Cefiderocol Susceptibility Results: a CLSI AST Subcommittee Advisory
Patricia J. Simner et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2023)
Global epidemiology and clinical outcomes of carbapenem-resistant Pseudomonas aeruginosa and associated carbapenemases (POP): a prospective cohort study
Jinnethe Reyes et al.
LANCET MICROBE (2023)
Poor in vitro activity of ceftazidime/avibactam, ceftolozane/tazobactam, and meropenem/vaborbactam against carbapenem-resistant Pseudomonas aeruginosa in India: Results from the Antimicrobial Testing Leadership and Surveillance (ATLAS) program, 2018-2021
Yu-Lin Lee et al.
JOURNAL OF INFECTION (2023)
Systematic review on estimated rates of nephrotoxicity and neurotoxicity in patients treated with polymyxins
Florian Wagenlehner et al.
CLINICAL MICROBIOLOGY AND INFECTION (2021)
Efficacy of human-simulated bronchopulmonary exposures of cefepime, zidebactam and the combination (WCK 5222) against MDR Pseudomonas aeruginosa in a neutropenic murine pneumonia model
James M. Kidd et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2020)
Comparative Evaluation of the In Vitro Activities of WCK 5222 (Cefepime-Zidebactam) and Combination Antibiotic Therapies against Carbapenem-Resistant Pseudomonas aeruginosa
Elias M. Mullane et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)
Effective inhibition of PBPs by cefepime and zidebactam in the presence of VIM-1 drives potent bactericidal activity against MBL-expressing Pseudomonas aeruginosa
Bartolome Moya et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2020)
In Vitro Activity of WCK 5222 (Cefepime-Zidebactam) against Worldwide Collected Gram-Negative Bacilli Not Susceptible to Carbapenems
James A. Karlowsky et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)
In Vitro Activity of Cefiderocol, a Siderophore Cephalosporin, against Multidrug-Resistant Gram-Negative Bacteria
Shazad Mushtaq et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)
International Consensus Guidelines for the Optimal Use of the Polymyxins Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP)
Brian T. Tsuji et al.
PHARMACOTHERAPY (2019)
Ceftazidime/avibactam alone or in combination with aztreonam against colistin-resistant and carbapenemase-producing Klebsiella pneumoniae
Aurelie Jayol et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2018)
Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial
Mical Paul et al.
LANCET INFECTIOUS DISEASES (2018)
Dominance of International High-Risk Clones in Carbapenemase-Producing Pseudomonas aeruginosa: Multicentric Molecular Epidemiology Report from India
Agila Kumari Pragasam et al.
INDIAN JOURNAL OF MEDICAL MICROBIOLOGY (2018)
In vitro activity of cefepime/zidebactam (WCK 5222) against Gram-negative bacteria
David M. Livermore et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2017)
Can Ceftazidime-Avibactam and Aztreonam Overcome β-Lactam Resistance Conferred by Metallo-β-Lactamases in Enterobacteriaceae?
Steven Marshall et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
分享论文
